Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2020-06-29 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
2020年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 2020 first extraordinary general meeting of shareholders of TianShiLi Pharmaceutical Group Co., Ltd. It includes voting results on multiple proposals related to the company's business activities, such as the spin-off and listing of a subsidiary, major asset sales, and related legal and procedural confirmations. The document contains detailed voting statistics, meeting attendance, and legal witness statements. This type of document is a formal announcement of voting results from a shareholders' meeting, not the meeting materials themselves or a full annual or interim report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content confirm it is not a brief report publication announcement or a regulatory filing. Confidence is high due to the explicit voting results and meeting details provided.
2020-06-29 Chinese
内蒙古建中律师事务所《关于对天士力医药集团股份有限公司重大资产出售草案信息披露的问询函》的专项法律意见书
Audit Report / Information Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a major asset sale by Tianjin Tasly Pharmaceutical Group Co., Ltd. It addresses inquiries from the Shanghai Stock Exchange about the disclosure of the asset sale draft, including detailed legal and financial arrangements, guarantees, compensations, and shareholder matters related to the transaction. The document references a major asset sale, legal opinions on the transaction, and related contractual and financial details. It is not a full annual or interim financial report, earnings release, or a simple announcement. It is a specialized legal opinion report related to a significant asset sale transaction, which fits the category of Audit Report / Information (AR) as it includes legal audit opinions and detailed legal disclosures related to the transaction, but is not the full annual report or financial statements. The document length and content confirm it is a substantive report rather than a brief announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2019
2020-06-28 Chinese
内蒙古建中律师事务所关于天士力医药集团股份有限公司本次交易相关内幕知情人买卖上市公司股票情况的自查报告的核查意见
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion report issued by a law firm regarding the self-inspection report on insider trading activities related to a major asset restructuring transaction of a listed company (Tianshili Pharmaceutical Group Co., Ltd.). It includes detailed information about insider trading checks, declarations, and legal conclusions about whether insider trading occurred and if it poses legal obstacles to the transaction. The document is not a financial report, earnings release, or management discussion. It is a specialized legal verification report related to compliance and regulatory matters concerning insider trading and asset restructuring. This fits the category of Legal Proceedings Report (LTR), as it deals with legal compliance and regulatory issues related to insider trading and major asset restructuring.
2020-06-28 Chinese
天健会计师事务所关于上海证券交易所《关于对天士力医药集团股份有限公司重大资产出售草案信息披露的问询函》的专项说明
Regulatory Filings
2020-06-28 Chinese
重大资产出售报告书（草案）（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产出售报告书（草案）（修订稿）" which translates to "Major Asset Sale Report (Draft) (Revised)". It includes detailed sections such as transaction overview, pricing, compliance analysis, financial statements of the asset to be sold, risk factors, and opinions from independent directors and financial advisors. The document is comprehensive and lengthy (15,000 characters), containing substantive financial data and detailed analysis related to a major asset sale transaction. This fits the definition of a Capital/Financing Update (CAP), as it provides updates on significant financing activities and changes in capital structure through asset sales. It is not an announcement of a report publication, nor a full annual or interim report, nor a regulatory filing or legal proceeding update. Therefore, the appropriate classification is CAP with high confidence.
2020-06-28 Chinese
关于上海证券交易所《关于对天士力医药集团股份有限公司重大资产出售草案信息披露的问询函》的回复公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement and response to an inquiry letter from the Shanghai Stock Exchange regarding a major asset sale plan by TianShiLi Pharmaceutical Group Co., Ltd. It includes extensive financial data, business analysis, market position, and strategic rationale for the asset sale. The content focuses on a significant asset disposal transaction, including financial advisor opinions and compliance with regulatory requirements for major asset restructurings. The document is lengthy (15,000 characters) and contains substantive financial and business information related to a major asset sale, not just an announcement of a report or a brief summary. It is not a full annual or interim report, nor an earnings release or call transcript. It is a regulatory disclosure related to a major asset restructuring, which fits best under the category of Regulatory Filings (RNS) as it is a regulatory response and detailed disclosure but not a formal financial report like a 10-K or IR. The document does not fit other categories such as M&A Activity (TAR) or Merger & Acquisition (MA) because it is a reply to an inquiry letter about a major asset sale, not a merger or acquisition filing per se. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2020-06-28 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.